Glamkast-AX Tablet SR is a sustained-release formulation combining Ambroxol (75mg), Levocetirizine (5mg), and Montelukast (10mg), designed to provide comprehensive management of respiratory conditions characterized by cough, allergy, and inflammation. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency and easing expectoration. Levocetirizine, a potent second-generation antihistamine, selectively inhibits peripheral H1 receptors, effectively reducing allergic symptoms such as rhinorrhea, sneezing, and nasal congestion without causing significant sedation. Montelukast, a leukotriene receptor antagonist, mitigates bronchoconstriction and inflammation by blocking leukotriene D4 receptors in the airways, contributing to improved respiratory function in conditions like asthma and allergic rhinitis. The sustained-release formulation ensures prolonged therapeutic effects, enhancing patient compliance by reducing dosing frequency. Glamkast-AX is indicated for the symptomatic relief of chronic bronchitis, asthma, allergic rhinitis, and other respiratory disorders where mucus hypersecretion, allergic reactions, and leukotriene-mediated inflammation coexist. It should be used under medical supervision, with caution advised in patients with hepatic impairment or known hypersensitivity to any component. This combination therapy offers a multifaceted approach to respiratory care, addressing mucus clearance, allergic response, and inflammatory pathways simultaneously.